Efficacy and safety of the type I interferon receptor inhibitor anifrolumab in patients with systemic lupus erythematosus (results of a 6-month study)

Efficacy and safety of the type I interferon receptor inhibitor anifrolumab in patients with systemic lupus erythematosus (results of a 6-month study)

Objective: to evaluate the efficacy and safety of the type I interferon (IFN) receptor inhibitor anifrolumab (AFM, Safnelo®) in patients with systemic lupus erythematosus (SLE) in real-life clinical practice over an observation period of 6 months.Material and methods. The prospective 6-month study i...

Full description

Saved in:
Bibliographic Details
Main Authors: T. M. Reshetnyak, E. A. Aseeva, A. A. Shumilova, N.  Yu. Nikishina, S. I. Glukhova, S. Yu. Shkireeva, A. M. Lila
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2024-04-01
Series:Современная ревматология
Subjects:
systemic lupus erythematosus
interferon receptors
interferon alfa
anifrolumab
Online Access:https://mrj.ima-press.net/mrj/article/view/1557
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items